When discussing patient adherence during clinical trials, most people will say that on average it is high and that the issue of non-adherence really surfaces during clinical care. But is this true or are we missing something in clinical trials? I think we are missing something, and the issue is far greater than we think it is.
Early drop-out during clinical trials has always been and still is an...
In the past few months the healthcare industry has sped up the adoption and implementation of digital remote healthcare solutions to meet patients’ health-related preferences and at the same time overcome the challenges of social distancing and limited human interaction. The pharmaceutical industry is also moving forward on the subject of virtual and hybrid clinical trials.
Growing costs of drug development
Over 95% of the clinical studies fail to meet their original time lines and budgets. Between 2006 and 2016 the global spending on drug development grew from $108 billion to over $148 billion. Clinical trials account for 45% to 75% of this cost and in 2012 the life sciences industry was already spending $1.2 billion on patient recruitment alone!
The more I read about patient centricity, the more I get the eerie feeling that there is something wrong, something missing. At first glance the concept is very clear, the strategy and tactics are right and the tools put to use all have an added value. But it still doesn’t feel quite right to me. So what is it?
Being responsible for business development, I fully understand why the...
It seems that nowadays patient centricity is a hot topic for everyone in the life science industry. Many articles are written about patient centricity, and more and more events and conferences use it as the main subject. But will the industry feel the same way about patient centricity a few years from now, or will it be discarded as just a lot of hot air?
We believe it is not and that it is the...